Patents Assigned to Theravalues Corporation
  • Publication number: 20240091173
    Abstract: To reveal which curcumin preparation, among various existing curcumin preparations, is effective for various symptoms of a common cold. Provided is an agent for relieving common cold symptom which contains, as an active ingredient, a curcumin-containing composition that contains fine particles of curcumin or turmeric pigment, or a mixture containing curcumin or turmeric pigment containing an amorphous thereof and a cellulose derivative.
    Type: Application
    Filed: December 6, 2022
    Publication date: March 21, 2024
    Applicant: THERAVALUES CORPORATION
    Inventor: Yoshitaka KUWABARA
  • Patent number: 11911348
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 27, 2024
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • Patent number: 11672770
    Abstract: A curcumin-containing composition has improved oral absorbability. An oral ingestion composition contains: (A) solid curcumin containing an amorphous body and/or an analog thereof; and (B) a solid water-soluble polymer which becomes viscous in an aqueous medium having a pH of 5 or more.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: June 13, 2023
    Assignee: THERAVALUES CORPORATION
    Inventors: Yuji Makino, Tsukasa Takahashi
  • Publication number: 20210023025
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Applicant: THERAVALUES CORPORATION
    Inventors: Yutaka KAWAKAMI, Tomonori YAGUCHI, Taeko HAYAKAWA, Atsushi IMAIZUMI
  • Patent number: 10849862
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: December 1, 2020
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • Patent number: 10245238
    Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: April 2, 2019
    Assignees: THERAVALUES CORPORATION
    Inventors: Hirofumi Takeuchi, Kohei Tahara, Atsushi Imaizumi, Tsukasa Takahashi, Takato Matsui, Hitomi Ozawa
  • Publication number: 20170239194
    Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.
    Type: Application
    Filed: May 14, 2015
    Publication date: August 24, 2017
    Applicants: THERAVALUES CORPORATION
    Inventors: Hirofumi TAKEUCHI, Kohei TAHARA, Atsushi IMAIZUMI, Tsukasa TAKAHASHI, Takato MATSUI, Hitomi OZAWA
  • Patent number: 9326990
    Abstract: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 3, 2016
    Assignees: THE UNIVERSITY OF TOKYO, THERAVALUES CORPORATION
    Inventors: Hiroyuki Morita, Ryozo Nagai, Atsuko Nakayama, Tadashi Hashimoto
  • Publication number: 20140194372
    Abstract: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.
    Type: Application
    Filed: July 19, 2012
    Publication date: July 10, 2014
    Applicants: THERAVALUES CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Morita, Ryozo Nagai, Atsuko Nakayama, Tadashi Hashimoto
  • Patent number: 8053461
    Abstract: A compound or a pharmaceutically acceptable salt thereof of the present invention is represented by the following general formula (I): [wherein, R1 to R8 may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9 (wherein R9 represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents a sulfur atom, an oxygen atom or NR10 (wherein R10 represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group or a C1-C6 alkoxy group)].
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: November 8, 2011
    Assignee: Theravalues Corporation
    Inventors: Noriaki Shinobu, Jun Shao, Masataka Kobayashi, Takao Mori
  • Patent number: 7824872
    Abstract: An objective of the present invention is to provide methods of screening for novel compounds that exhibit anticancer activity. The screening methods of the present invention comprise using serine/threonine kinase Pim-1, or partial peptides or salts thereof.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: November 2, 2010
    Assignee: Theravalues Corporation
    Inventors: Masanobu Kobayashi, Jian Chen
  • Publication number: 20100076049
    Abstract: A compound or a pharmaceutically acceptable salt thereof of the present invention is represented by the following general formula (I): [wherein, R1 to R8 may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9 (wherein R9 represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents a sulfur atom, an oxygen atom or NR10 (wherein R10 represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group or a C1-C6 alkoxy group)].
    Type: Application
    Filed: November 5, 2007
    Publication date: March 25, 2010
    Applicant: Theravalues Corporation
    Inventors: Noriaki Shinobu, Jun Shao, Masataka Kobayashi, Takao Mori